Program Seeks to Identify microRNA Biomarkers for Overall Survival and Risk
of Melanoma Metastasizing to Distant Sites
REHOVOT, Israel and NEW YORK, September 7 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a global leader in the field of microRNA and RNAi, announced today it will be working in collaboration with NYU Medical Center to leverage the significant potential of microRNA profiles to develop a diagnostic test for melanoma.
Rosetta Genomics believes its unique diagnostic engine has enabled it to discover the majority of known microRNA sequences for which it has submitted a series of patent applications. With this proprietary engine, Rosetta will screen more than 700 microRNAs (many of which are not publicly available) in order to identify the right signature which will potentially be able to quickly and efficiently find the right prognostic indicator test for harmful melanomas.
While this melanoma diagnostic test is still in the early stages, Rosetta Genomics plans to launch three diagnostic products in 2008 that include a test for cancer of unknown primary ("CUP") and two differential diagnostic tests related to lung cancer. The company will continue gradually to expand its pipeline with more diagnostic and eventually therapeutic applications.
"We see helping cure cancer as an incredibly important responsibility
for Rosetta Genomics. Much of our work surrounds discovering microRNA
biomarkers, and given how much is known about the connection between
microRNA and cancer, we believe that we are in a unique position to advance
the fields of cancer diagnosis, prognosis and therapeutics. This
collaboration with NYU will give both organizations an opportunit
|SOURCE Rosetta Genomics Ltd|
Copyright©2007 PR Newswire.
All rights reserved